Integra Therapeutics Raises €10.7M In Series A Round

Founded in 2020 by Dr. Marc Güell and Dr. Avencia Sánchez-Mejías as a Pompeu Fabra University spin-off, Integra Therapeutics created FiCAT a platform combining CRISPR-Cas precision with engineered piggyBac transposase to overcome key gene therapy challenges, including payload size, stability, and accuracy, for genetic, cancer, and autoimmune diseases.

Avencia Sánchez-Mejías, PhD, CEO and Co-Founder of Integra Therapeutics, shared: Thanks to the support of our investors, we will continue leading innovation in cell and gene therapies and are getting closer to transforming the treatment of complex diseases like cancer, autoimmune diseases and rare diseases.

Read Also - NRG Therapeutics Secures £50M In Series B Round

The funding round features €4 million from the EIC Fund and €2.7 million from CDTI Innvierte, part of Spain’s Ministry of Science, Innovation and University, alongside continued support from AdBio Partners, Columbus Venture Partners, Invivo Partners and Takeda Ventures.

Svetoslava Georgieva, Chair of the EIC Fund Board, commented: We are happy to announce EIC Fund’s investment in Integra Therapeutics. We empower them to accelerate the development of groundbreaking therapies that have the potential to transform lives and advance the field of gene therapy on a global scale.

The funding will enable Integra Therapeutics to integrate new advancements into the FiCAT platform, validate next-generation CAR-T therapies in preclinical studies, and expand cell engineering capabilities to support technology transfer to the pharmaceutical industry.

Simultaneously, the company is developing its first gene therapy for a rare pediatric liver disease, backed by an EIC Accelerator grant.

About Integra Therapeutics

Integra Therapeutics is a biotech company developing next-generation gene writing tools to treat genetic diseases. By combining CRISPR precision with the efficiency of viral integrases and transposases it enables highly effective, programmable delivery of large DNA sequences, offering a breakthrough approach to safe and precise gene therapies.